{"id":"W2565098019","doi":"10.1016/j.jhep.2016.10.020","title":"Retraction notice to: PS124 – Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals with Inflammatory Bowel Disease [J Hepatol 64 (2016) S199]","year":2016,"lang":"en","type":"retraction","venue":"Journal of Hepatology","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":1,"is_retracted":true,"has_abstract":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Vedolizumab; Primary sclerosing cholangitis; Medicine; Inflammatory bowel disease; Dosing; Gastroenterology; Ulcerative colitis; Internal medicine; Notice; Inflammation; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}